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Abstract 
 
Objective(s) 
Single injection of naloxone, a selective antagonist of morphine, prior to the drug conditioning testing was 
used to investigate on morphine dependence. 
Materials and Methods 
Conditioning to morphine (2.5-10 mg/kg, s.c.) was established in  adult  male  Wistar  rats  (weighing           
200-250 g) using an unbiased procedure. Nitric oxide agents were microinjected into the central amygdala 
prior to naloxone-paired place conditioning testing. 
Results 
The results showed that morphine produced a significant dose-dependent place preference in animals. 
Naloxone (0.1-0.4 mg/kg, i.p.) injections pre-testing of the response to morphine (7.5 mg/kg, s.c.) caused a 
significant aversion at the higher doses (0.4 mg/kg, i.p.). This response was reversed by microinjection of         
L-arginine (0.3-3 µg/rat, intra-central amygdala) prior to naloxone on the day of the testing. The response to 
L-arginine was blocked by pre-injection of N
G-nitro-L-arginine methyl ester (L-NAME) (intra-central 
amygdala). 
Conclusion 
A single injection of naloxone on the test day of morphine place conditioning may simply reveal the 
occurrence of morphine dependence in rats, and that the nitric oxide in the central amygdala most likely 
plays a key role in this phenomenon.  
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Introduction 
Much evidence indicates that the chronic 
usage of morphine produces physical and 
psychological dependence characterized by the 
expression of withdrawal symptoms upon 
cessation of the drug (1-5). Morphine is also 
implicated in reward (6-8) because of 
enhanced dopamine release in shell of 
accumbens by doubling of the firing rate of 
dopamine projecting neurons from the ventral 
tegmental area (9). Place conditioning is a 
simple and an effective method to assess the 
rewarding properties of drugs (10-17). It has 
been demonstrated that morphine-induced 
place preference is mediated by mu-opioid 
receptors (13, 14, 18-20) to which binding of 
the opioids, enhances the level of extracellular 
dopamine in the amygdala (7, 8, 21).  
Naloxone, a selective antagonist is able to 
neutralize the opioid effect by competing for 
the same receptor sites (19). Some authors 
have notified that infusion of naloxone into the 
ventral tegmental area or periaqueductal gray 
blocks the acquisition of morphine place 
preference (22). In contrast, systemic 
administration of naloxone potentiated the 
expression of morphine-conditioned place 
preference (CPP) in experimental animals 
(23). Moreover, injection of naloxone in 
morphine-dependent Swiss-Webster mice has 
shown a significant increase in mu-opioid 
receptor expression during opioid withdrawal 
in some brain areas including amygdala (24). 
This antagonist has been shown to precipitate 
the withdrawal symptoms after a short-term 
infusion or even a single dose injection both in 
humans and animals (25).  
Nitric oxide, a chemical of great importance 
(26) and a main retrograde neurotransmitter 
(27) is produced postsynaptically in response 
to the activation of central excitatory amino 
acids. Nitric oxide plays a role in the 
regulation of behavior (28), and is implicated 
in the actions of opiates (29). Morphine 
stimulates the release of nitric oxide in 
amygdala through a sensitive route for the 
naloxone and N
G-nitro-L-arginine methyl ester 
(L-NAME) (17), the fact demonstrating that 
the nitric oxide in limbic system modulates the 
morphine-induced psychological dependence. 
Despite this evidence, little is known about the 
mediation of the psychological dependence 
which is supposed to be induced by a limited 
period of morphine therapy used to establish a 
place preference by the drugs of abuse. 
Therefore, in the present study, we tried to 
examine the morphine conditioning in the task 
paired with a single pretesting injection of 
naloxone to address the drug dependence more 
deeply, and investigating the possibility of the 
nitric oxide production in the central amygdala 
in the process of morphine dependence in 
Wistar rats. 
 
 
Materials and Methods 
Subjects 
Adult male Wistar rats weighing 200-250 g 
(Pasteur Institute, Tehran, Iran) were housed in 
standard plastic cages in groups of 2 in a 
controlled  colony  room  (temperature               
21±3 °C). They were maintained on a 12 hr 
light/dark cycle (lights on at 07.00 a.m.) with 
food and water ad libitum. The experiments 
were carried out during the light phase of the 
cycle. Each animal was tested once. Six to 
eight animals were used per groups which 
were killed by overdose of chloroform at the 
end of each experiment. All experiments were 
done in accordance with the National Institutes 
of Health Guide for the Care and use of 
laboratory animals approved by the local 
ethical committee of Shahed University 
(Document No: 7941). 
 
Drugs 
Morphine sulphate (Temad, Co., Tehran, Iran) 
was prepared freshly in sterile 0.9% NaCl 
solution, and injected subcutaneously (s.c.). 
The intraperitoneal (i.p.) injection volume of 
naloxone hydrochloride (Tolid-Daru Co., 
Tehran, Iran) was 1 ml/kg for all groups. 
Vehicle  was  0.9%  physiological  saline.         
L-Arginine (Sigma Chemical Co., USA) and 
N
G-nitro-L-arginine methyl ester (L-NAME; 
Research Biochemical Inc., USA) were also 
prepared freshly in sterile 0.9% NaCl solution. 
Nitric oxide  agents,  L-arginine  and/or                
L-NAME were bilaterally injected into the 
area of interest (central amygdala) in a volume 
of 1.0 µl/rat. Vehicle was 0.9% physiological 
saline as well. . Ketamine (Veterinary  
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organization of Iran) at the dose of 100 mg/kg 
i.p. was used to anesthetize the experimental 
animals.  
  
Stereotaxic surgery 
The animals were anesthetized and placed in a 
stereotaxic apparatus, with the incisor bar set 
at approximately 3.3 mm below horizontal 
zero to achieve a flat skull position. An 
incision was made to expose the rat skull. Two 
holes were drilled in the skull at stereotaxic 
coordinates: AP= -2.12 mm posterior to 
bregma, and L= ±4.1 mm according to the 
atlas of Paxinos and Watson (30). Two guide 
cannulae (21-Gauge) were inserted into the 
holes. For animals receiving bilateral 
injections into the central amygdala, the guide 
cannulae were lowered 6 mm below bregma 
through the holes drilled at the desired 
coordinates. The guide cannulae were 
anchored with a jeweler’s screw, and the 
incision was closed with dental cement. After 
surgery, dummy inner cannulae inserted into 
the guide cannulae and left in the place until 
injections were made. All animals were 
allowed to being recovered for 1 week before 
the beginning of the behavioral testing. 
 
 
Intra-central amygdala injection 
The animals were gently restrained by hand; 
the dummy cannulae were removed from the 
guide cannulae. Drugs were directly injected 
into the nucleus through guide cannulae by 
using injection needles (27-Gauge) connected 
by polyethylene tubing (0.3 mm internal 
diameter) to a 5.0 µl glass Hamilton syringe. 
The injection needles projected a further 1.8 
mm ventral to the tip of the guides. The 
injection volume was 1.0 µl for all groups that 
was made over a 30 sec period; and the 
injection cannulae were left in the guide 
cannulae for an additional 60 sec to facilitate 
the diffusion of the drugs.  
 
Conditioning place preference apparatus and 
paradigm 
Place Conditioning Apparatus 
A two compartment conditioned place 
preference (CPP) apparatus (30×60×30 cm) 
was used in these experiments. Place 
conditioning was conducted using an unbiased 
program, with a little change to the previously 
described design (17, 31, 32): the apparatus 
was divided into two equal-sized 
compartments. In the middle of the apparatus a 
removable wall was inserted. Both 
compartments were completely colored white 
but striped black differently (vertical vs. 
horizontal). The compartments were also 
distinguishable by texture and olfactory cues. 
To provide the tactile difference between the 
compartments, one of the compartments was 
floored smooth vs. the other compartment 
which was grinded. A drop of natural aqueous 
rose extract was placed at the corner of the 
compartment equipped with a textured floor, 
to provide the olfactory difference between the 
compartments. In this apparatus, rats displayed 
no consistent preference for one of the 
compartments, confirming that this procedure 
was unbiased. All experiments were recorded 
using an Ethovision system equipped with a 
video camera which was located 120 cm above 
the apparatus. In addition, the video files were 
then reviewed by an observer who was blind to 
the experiments.  
 
Conditioning paradigm 
The conditioning paradigm consisted of three 
phases.  
 
Pre-conditioning (familiarization) phase 
On day 1, animals received one habituation 
session. They were placed in the middle line of 
the apparatus and allowed free access to the 
entire apparatus for 15 min, while the 
removable wall was raised 12 cm above the 
floor. The time spent by rats in each 
compartment was recorded by using the 
Ethovision system and by an observer who 
was blind to the treatments after reviewing the 
video files.  
 
Conditioning phase 
This phase was started one day after the 
familiarization. The conditioning phase 
consisted of 3-saline and 3-drug pairings; the 
animals were daily injected with drug or saline 
with a 6 hr interval. Drug administration in 
conditioning phase was carried out during the 
light phase of a 12 hr light/dark cycle (e.g. at  
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09.00 am and 03.00 pm). Control groups 
received saline (1 ml/kg, s.c.) twice a day with 
a 6 hr interval. The duration of all conditioning 
sessions was 45 min. During these sessions the 
removable wall was inserted along the seam 
separating the two compartments. For each 
drug dose, animals were randomly assigned 
into groups of 8 rats. Then, the groups were 
injected with drug and confined in a 
compartment for drug pairing (drug-paired 
side). The drug treatment for half of the groups 
was paired with one compartment, while for 
the other half it was paired with the other 
compartment (13, 16, 17, 33). The presentation 
order of morphine and saline were 
counterbalanced for each drug dose.  
 
Post-conditioning (testing) phase 
Test sessions were carried out on day 5, one 
day after the last conditioning session, in a 
morphine-free state. Each animal was tested 
only once. For testing, the removable wall was 
raised 12 cm above the floor and each control 
animals was allowed free access to both 
compartments of the apparatus for 15 min. The 
time spent in both compartments was then 
assessed. The time spent in the drug-paired 
compartment on testing day minus that of 
spent in the same compartment on day of the 
familiarization, representing the score of 
change in place preference (in sec), was 
expressed as mean ± SEM.  
 
Experimental design 
Induction and assessment of morphine place 
conditioning 
The effects of administration of morphine (2.5, 
5, 7.5 and 10 mg/kg; s.c.) on induction of 
place conditioning in animals were 
determined. Each different doses of morphine 
or saline was injected in a 3-day schedule of 
conditioning  task  as  described  in  detail           
in section 2.4. The time spent in the drug-
paired  compartment  on  the  test  day                     
(post-conditioning phase) minus that of spent 
in the same compartment on the day of the 
familiarization (pre-conditioning phase) was 
calculated to assess the CPP induction. Each 
drug dose was tested in 8 animals which were 
examined only once. Animals were tested in a 
morphine-free state which may eliminate the 
influence of morphine-induced motor effects 
on the response (16, 22, 34). 
 
Effects of naloxone, an antagonist of mu-
opioid receptor, in a morphine conditioning 
procedure 
In this set of experiments, single injections of 
different doses of naloxone (0.1-0.4 mg/kg, 
i.p.) were done on the test day (post-
conditioning phase), 10 min before the 
morphine place conditioning test. The time 
spent in the drug-paired compartment on the 
test day minus that of spent in the same 
compartment on the pre-conditioning day 
(familiarization day) was calculated to assess 
the response induction by the drugs. Animals 
were tested in a morphine-free state. 
 
Effects of intra-central amygdala nitric oxide 
agents either alone or in combination with 
single injection (i.p.) of naloxone in the 
morphine conditioning task  
To determine the effects of different doses of 
intra-central amygdala L-arginine or L-NAME 
(0.3-3 µg/rat) on morphine-CPP, alone or in 
combination with naloxone, the agents were 
bilaterally administered 1-2 min before the 
morphine place conditioning test or injection 
of naloxone on the test (post-conditioning) 
day. These agents (0.3-3 µg/rat, intra-central 
amygdala) were pre-administered (1-2 min) to 
naloxone before morphine response testing to 
determine the interaction between the drugs. 
Naloxone (0.4 mg/kg, i.p.) was injected 10 
min prior to the morphine (7.5 mg/kg, s.c.) 
place conditioning test. Control groups were 
simply received saline (1 µl/rat intra-central 
amygdala or 1 ml/kg, i.p.). 
 
Histological verification 
After completion of behavioral testing, 
animals were killed with an overdose of 
chloroform. Ink (0.5 µl of 1% aquatic 
methylene blue solution) was injected into the 
guide cannulae, using 27-Gauge injection 
cannulae that projected a further 1.8 mm 
ventral to the tip of the guides, to aid in 
histological verification. Brains were removed 
and fixed in a 10% formalin solution for 48 hr  
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before sectioning. Brain slices were taken 
through the brain areas of cannulae 
placements, and the cannulae placements were 
verified (Figure 1) using the atlas of Paxinos 
and Watson (2005). Data from rats with 
injection sites located outside the appropriate 
area were excluded from the statistical 
analyses.  
 
Statistical analysis 
All results were expressed as mean±SEM 
(standard error of mean). In order to compare 
the changes in place preference (sec) obtained 
in all groups (vehicle and experimental 
groups), one- and/or two-way analysis of 
variance (ANOVA) followed by appropriate 
post-hoc analysis (Tukey’s test) for multiple 
comparisons were used, as needed. P-values 
less than 0.05 (P< 0.05) were considered to be 
statistically significant. 
 
Results  
Histological verification of microinjection 
sites in the central amygdale 
Figure 1 reveals the injection site intra-central 
amygdala after administration of 1 µl of a 
methylene blue solution by using the same 
injection set up as used for the drugs.  
 
Dose-response of morphine in conditioning 
place preference paradigm 
Figure 2 shows the effect of different doses of 
morphine (2.5-10 mg/kg, s.c.) in CPP 
paradigm  in Wistar rats. Administration of 
morphine resulted in a significant response in 
comparison with the saline group (F4,35= 
3.258;  P< 0.05). The opioid induced a 
meaningful preference to the place dose-
dependently. In view of the results, morphine 
at the dose of 7.5 mg/kg (s.c.) was used for the 
subsequent studies.  
 
Effect of naloxone on the expression of 
morphine response in the place conditioning 
procedure 
Figure 3 shows the effect of single injection of 
different doses of naloxone (0.1-0.4 mg/kg, 
i.p.) prior to morphine response. Pre-testing 
administration of naloxone in experimental 
animals, which were morphine (7.5 mg/kg, 
s.c.) injected, resulted in a significant effect as 
compared to the control group in morphine-
CPP. The two-way ANOVA indicated  the 
interaction (Fdrug(1,70)=7.383,  P< 0.05; 
Fdose(4,70)=2.221, P< 0.05: Fdrug*dose(4,70)=2.997, 
P< 0.05). Further analysis demonstrates that 
despite the fact that the antagonist did not 
induce any response alone; the narcotic drug, 
when injected on day of the test in morphine-
administered animals, reversed the effect of 
morphine effective dose in a dose- dependent 
manner. In view of the results, naloxone at the 
highest dose (0.4 mg/kg, i.p.) was used for the 
subsequent studies.  
 
Effect of nitric oxide production in the 
central amygdala on the naloxone-modulated 
morphine response in the place conditioning 
paradigm  
Pre-testing  injection  of  single  doses  of               
L-arginine or L-NAME (0.3, 1.0 and 3.0 µg/rat, 
intra-central amygdala) resulted no significant 
effect in the animals which were simply injected 
saline (1 ml/kg, s.c.), during the conditioning 
procedure (Figure 4 and Figure 5). On the other 
hand,  bilateral  injection  of  L-arginine  but  not        
L-NAME (0.3, 1.0 and 3.0 µg/rat, intra-central 
amygdala),  prior  (1-2  min)  to  the  injection          
of  naloxone  (0.4  mg/kg,  i.p.)  before  testing       
of morphine response (7.5 mg/kg, s.c.), resulted 
in a significant effect (Figure 5) compared to the 
control group. Analysis by two-way ANOVA 
revealed the interaction between drugs 
(Fdrug(1,56)= 0.891, P> 0.05; Fdose(3,56)= 7.750, P< 
0.0001: Fdrug*dose(3,56)=9.245, P< 0.0001). Further 
analysis indicated that L-arginine reversed the 
response to naloxone. This effect was blocked 
by L-NAME (0.3, 1.0 and 3.0 µg/rat, intra-
central amygdala) prior to the injection of L-
arginine effective dose (0.3 µg/rat, intra-central 
amygdala) before the administration of naloxone 
pre-testing (F3,28= 6.791, P<  0.01) (Figure 6). 
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Figure 1. A Cannulae placements in central amygdala 
evidenced by ink injection in a volume of 1 µl/rat by using 
the same set up as used for intra-central amygdala injection 
of drugs (AP: -2.12). 
B: Verification from atlas of Paxinos and Watson (2005). 
 
 
 
 
Figure 2. Dose response curve for morphine-induced 
conditioned place preference in opioid-naive male 
Wistar  rats.  Morphine  (2.5-10  mg/kg)  or  saline                 
(1 ml/kg) was given subcutaneously (s.c.) in a 3-day 
schedule of an unbiased conditioning paradigm. The 
control group received saline (1 ml/kg, s.c.), twice daily 
for 3 days. Data are expressed as mean of change in 
place preference±SEM. Change in place preference is 
defined as the time spent in the drug-paired place on day 
of testing minus that spent in the same place during pre-
conditioning.  
Tukey-Kramer  post hoc analysis showed the 
differences:  
*P< 0.05, and **P< 0.01 difference to control (sal-sal).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Naloxone response curve in morphine treated 
male rats. Naloxone (0.1-0.4 mg/kg) was given 
intraperitoneally (i.p.) on day of the testing of place 
conditioning to morphine (7.5 mg/kg, s.c.). The rats 
were first injected with naloxone, and after 10 min they 
were tested in a morphine-free state. Control group 
simply received saline (1 ml/kg, i.p.) pre-testing. Data 
are expressed as mean of change in conditioning±SEM.  
**P< 0.01 difference compared to the negative control 
(sal-sal).   
##P< 0.01 difference compared to the positive control 
(sal-mor).   
+++P< 0.001 difference compared to the respective 
dose groups according to post hoc measurements.   
 
 
 
 
   
Figure 4. Response curve induced by single injection of 
L-arginine (0.3-3 µg/rat, intra-central amygdala) pre-
testing, in the control task or prior to naloxone injection 
before morphine response testing. 10 min after saline       
(1 ml/kg, i.p.) or naloxone injection (0.4 mg/kg, i.p.) the 
rats were tested in a morphine-free state. Data are 
expressed as mean of change in conditioning±SEM.  
**P<  0.01  difference  compared  to  saline  control       
(sal-sal)  
#  P< 0.05, and ## P< 0.01 differences compared to 
positive control (sal-mor-nal) 
+++P< 0.001 interaction between the respective dose 
groups according to post hoc measurements.   
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Figure 5. Response curve induced by single injection of 
L–NAME (0.3-3 µg/rat, intra-central amygdala) pre-
testing in the control task or prior to naloxone before 
morphine response testing. 10 min after saline (1 ml/kg, 
i.p.) or naloxone injection (0.4 mg/kg, i.p.) the rats were 
tested in a morphine-free state. Data are expressed as 
mean of change in conditioning±SEM.  
**P<  0.01  difference  compared  to  saline  control        
(sal-sal).  
 
 
 
Figure 6. Response curve induced by prior injection of 
L-NAME (0.3-3 µg/rat, intra-central amygdala) prior to 
L-arginine before the injection of naloxone (0.4 mg/kg, 
i.p.) on day of testing of morphine response. 10 min 
after naloxone injection, the rats were tested in a 
morphine-free state according to the schedule of 
conditioning paradigm. The control group was injected 
with saline       (1 µg/rat, intra-nucleus or 1 ml/kg, i.p.) 
with respect to the way of injection of the desired drug 
prior to testing. Data are expressed as mean of change in 
conditioning±SEM.  
**P< 0.01 difference compared to control (sal). 
 
Discussion 
In this study, morphine (2.5, 5, 7.5 and 10 
mg/kg, s.c.) induced a significant conditioned 
dose-dependent place preference in male 
Wistar rats. This effect may reflect the role of 
the mu- and delta- opioid receptors (20, 35) as 
well as several neuronal systems (13) 
including glutamate and GABAB receptors 
(36) in the mediation of the morphine 
rewarding in rats. 
Injection of naloxone (0.1-0.4 mg/kg, i.p.) 
before the morphine (7.5 mg/kg, s.c.)-CPP test 
in the post-conditioning phase (test day), 
induced a significant place aversion. It 
indicates an opioid system involvement (37) in 
the morphine dependence in a place preference 
paradigm measured by an unbiased task with 
no pre-conditioning preference. In accordance, 
previous studies have shown an aversive effect 
of naloxone by using either a biased (38) or a 
balanced biased procedure with no strong 
preconditioning preferences (39, 40). Our 
results, for the first time, may indicate that the 
style of the protocol (biased vs. unbiased) 
designed to analyze the dependence on 
morphine in the conditioning, by using a single 
injection of the antagonist prior to opioid 
response, does not play a role in displaying of 
the drug dependency. In addition, it seems that 
the same subtypes of the receptors might be 
involved in the observed interaction. In 
contrast, a reinforcing property of naloxone in 
the process has been reported in those cases in 
which the intraperitoneal route of the 
administration of the antagonist was chosen in 
the protocol (41). Other studies also indicated 
that high doses of naloxone inhibit the 
expression of morphine place conditioning in 
mice (3, 42). In a previous survey on acute 
morphine dependence, the magnitude of 
naloxone potency to precipitate morphine 
withdrawal is shown to be depended to 
morphine dose (43). Although there is no 
molecular evidence to elucidate the 
mechanism governing the effect observed in 
the present study, it might lead in a conclusion 
that this property of naloxone is mediated 
through the activation of the same subtype 
opiate receptors (40) which are involved in the 
conditioning to the drugs of abuse. Other 
explanation might be that different subtypes of 
opioid receptors are involved in this effect 
since the role of kappa-opioid receptors has 
been demonstrated both in the development of 
physical and psychological dependence on 
morphine (44) and the precipitation of the 
withdrawal signs by naloxone as well (45). It 
is recently noted that both mu and GABAA 
receptors in the central amygdala inhibit the 
behaviors induced by withdrawal from acute  
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morphine treatment (46). There is also 
evidence expressing that the central amygdala 
is involved in place aversion induced by 
naloxone in single-dose morphine-treated rats 
(47). Previous studies proposed the role of 
several neurotransmitter systems in the 
expression of morphine place conditioning 
(13, 14). 
Nitric oxide also participates in morphine-
induced CPP (17, 48-51). The role of the nitric 
oxide at the central amygdala in morphine 
CPP has already been proposed by this 
laboratory (17), but, role of nitric oxide system 
in the central amygdala in naloxone place 
aversion was evaluated in the present work for 
the first time. A repeated morphine injection 
(3-sessions) was used to associate between 
primary unconditioned properties of the 
environment and the conditioned stimulus 
(13). But, Ishida et al (2008) used a single-
session morphine treatment to survey on the 
acute dependence. Although single injection of 
the L-arginine (0.3-3 µg/rat, intra-central 
amygdala) as a nitric oxide precursor showed 
no significant effect in the control task, present 
observations  demonstrated  that  injection  of       
L-arginine before naloxone injection produces 
a significant effect on naloxone-induced 
responses. The data may reflect that nitric 
oxide as a candidate for modulating morphine 
dependence in the central amygdala 
participates in the acute (psychological) 
dependence on morphine which was exhibited 
in the avoidance of the conditioned place 
because of interaction between naloxone and 
morphine. L-NAME (0.3-3 µg/rat, intra-
central amygdala) blocked this effect when 
microinjected in combination with L-arginine. 
However, sole injection of L-NAME did not 
show any significant effect compared to the 
control groups in morphine-induced CPP. 
Therefore, it can be suggested that L-arginine 
may cause an activation of the nitric oxide 
system in central amygdala which 
consequently interacts with naloxone to 
present the dependence on the opioid in the 
naloxone-paired morphine conditioning test. It 
can be supported by the finding that different 
neural systems mediate morphine reward and 
the spontaneous withdrawal signs in the acute 
dependence (15). 
Although, the role of the opioid system in 
the acute dependency is not obviously defined 
to date, nevertheless, this work may clearly 
indicate that both opioid and non-opioid 
mechanisms modulate this effect, the fact that 
the nitric oxide, a highly active 
neurotransmitter, in the central amygdala may 
mediate the pharmacological effects of the 
morphine and naloxone at the molecular level, 
remains to be studied.  
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